Linda Neuman

VP, Clinical Development Consultant
Catalyst Biosciences

Presentation(s):

• OC 40.5 - Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors

  Monday, July 11, 2022
  3:45 PM – 4:00 PM